VYNE reports Q4/FY 2023 loss; cash $93.3M; VYN201 Phase 2b starts Q2 2024; VYN202 Phase 1a expected Q2 2024

VYNE Therapeutics Inc.

2023-FY EPS reported -$2.78 revenue$424,000

Cash, cash equivalents, restricted cash and marketable securities $93.3M at Dec 31, 2023, providing runway through end of 2025.
GAAP loss from continuing ops Q4 2023 $6.15M vs $7.76M in Q4 2022; full year $27.87M vs $33.95M (improved YoY).
Adjusted net loss Q4 2023 $5.48M vs $8.88M; full year $25.15M vs $18.91M (wider YoY for FY).
VYN201 Phase 2b trial in nonsegmental vitiligo to begin Q2 2024; top-line results mid-2025; gel formulation selected.
VYN202 IND submitted Dec 2023; FDA requested additional nonclinical study; completed consistent with expectations; Phase 1a expected Q2 2024 if FDA clears.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

VYNE Therapeutics Inc. reported financial results for the fourth quarter and year ended December 31, 2023.

Period: the fourth quarter and year ended December 31, 2023
Result: reported results

Exact text from the filing

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the fourth quarter and year ended December 31, 2023 and provided a business update.

View on SEC.gov

Browse all earnings releases →

VYNE Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-029097

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.